Inclusion Criteria:

- Renal cell carcinoma with a predominant clear cell component confirmed by histology.

- Advanced disease: metastatic AND, not suitable for resection

- Male or female, aged 18 years or older

- ECOG (Eastern Cooperative Oncology Group) Performance Status of 0 or 1

- Low or intermediate MSKCC (Memorial Sloan Kettering Cancer Center) prognostic risk
score,i.e. no more than 2 of the following:

- Karnofsky performance status (<80%)

- Low serum hemoglobin (≤ 13 g/dL for males and ≤ 11.5 g/dL for females)

- High corrected serum calcium (≥ 10 mg/dL)

- Target and/or non-target lesions according to RECIST 1.1 ( Response Evaluation
Criteria in Solid Tumors)

- Expected survival of at least 3 months.

- No prior systemic treatment. But adjuvant treatment is ok if stopped from ≥ 24 months

- Adequate bone marrow function as shown by:

- Adequate liver function as shown by:

- Adequate renal function as shown by serum creatinine ≤ 1.5 x ULN (upper limit of
normal)

- Left ventricular ejection fraction ≥55% on gated cardiac blood pool scan, or normal
left ventricular function and fractional shortening on echocardiogram (according to
institutional limits).

- SBP (systolic blood pressure) ≤140mmHg and DBP (diastolic blood pressure)

- 90mmHg (it is acceptable to initiate antihypertensive treatment prior to
registration to achieve these goals).

- Able to commence treatment within 7 days of registration.

- Willing and able to comply with follow-up and all other protocol requirements.

- Written informed consent

Exclusion Criteria:

- Prior treatment with VEGF-targeting agents or multi-kinase inhibitors or
mTOR-targeting agents

- Active central nervous system metastases.

- Other malignancy diagnosed within the last 5 years, except the following if
adequately treated: superficial squamous cell carcinoma or basal cell carcinoma of
skin, superficial bladder cancer (T1 and G1 or T1 and G2), stage 1 cervical cancer.

- Treatment with an investigational agent in the last 4 w.

- Known to be HIV positive.

- Evidence of chronic hepatitis due to hepatitis B virus (HBV) or hepatitis C virus
(HCV)

- Clinically significant heart disease (NYHA Class III or IV)

- History of hypertension requiring hospitalization.

- Other serious illnesses,

- Immunotherapy or chemotherapy in the last 4 w (6 weeks for nitrosoureas)

- Major surgery in the last 4 w, or planned in the next 6 w

- Radiation therapy in the last 2 w, or planned in the next 6 w

- NCI CTCAE (Common Toxicity Criteria for Adverse Effects) version 4.0 grade 3 or worse
hemorrhage in last 4 w.

- Any of the following in the last year: myocardial infarction, severe/unstable angina,
coronary/peripheral artery bypass graft, symptomatic congestive heart failure,
cerebrovascular accident or transient ischemic attack, or pulmonary embolism.

- Pre-existing thyroid abnormality with thyroid function that cannot be maintained in
the normal range with medication.

- Ongoing cardiac dysrhythmias of NCI CTCAE version 4.0 grade ≥2, atrial fibrillation
of any grade, or prolongation of the corrected QT interval (QTc) to >450 msec for
males or >470 msec for females

- Uncontrolled diabetes as defined by fasting serum glucose >1.5 X ULN.

- Pregnancy,lactation. Inadequate contraception.

- Known allergy or hypersensitivity to everolimus, sunitinib or iodine.

- Medical or psychiatric condition that compromises the patient's ability to give
informed consent.